Optic Perineuritis

Clinical and Radiographic Features

Valerie Purvin, MD; Aki Kawasaki, MD; Daniel M. Jacobson, MD

Background: Optic perineuritis is an uncommon variety of orbital inflammatory disease that is distinct from demyelinating optic neuritis.

Objective: To describe the clinical and radiographic features of idiopathic optic perineuritis, with particular emphasis on those features that help to distinguish this condition from optic neuritis.

Methods: We reviewed the medical records of 14 patients with optic perineuritis who were seen in 2 neuro-ophthalmology clinics.

Results: Patients ranged in age from 24 to 60 years; 5 were older than 50 years. All patients had visual loss, eye pain, or both. The visual acuity was 20/20 or better in 8 of the 15 eyes. The results of visual field testing were normal in 2 eyes, and a paracentral scotoma or an arcuate defect was seen in 7. Magnetic resonance imaging scans demonstrated circumferential enhancement around the optic nerve, sometimes with intraorbital extension. Response to corticosteroids was dramatic; however, 4 patients had a relapse with lowering of the dose.

Conclusions: In contrast to those with optic neuritis, patients with optic perineuritis are often older at onset and are more likely to show sparing of central vision. Magnetic resonance imaging scans demonstrate enhancement around, rather than within, the optic nerve. Response to corticosteroids is more dramatic than in patients with optic neuritis, and patients are more likely to experience recurrence after stopping treatment.

Arch Ophthalmol. 2001;119:1299-1306

Optic perineuritis (OPN), also termed perioptic neuritis, is an uncommon inflammatory disorder involving the optic nerve sheath. Historically, the term has been used to describe several different clinical entities. In recent years, OPN has generally been understood to represent a form of idiopathic orbital inflammatory disease, in which the specific target tissue is the optic nerve sheath. While most cases are isolated and idiopathic, OPN occasionally occurs as a manifestation of a specific infectious or inflammatory disorder, such as Wegener granulomatosis or giant cell arteritis.

Radiographically, OPN may simulate optic nerve sheath meningioma, but clinically it is more likely to be mistaken for acute demyelinating optic neuritis (ON). In both OPN and ON, patients typically experience acute monocular visual loss, pain with eye movement, and either a normal or a swollen optic disc. The natural history of and response to treatment for these 2 conditions, however, may differ.

The 14 patients included 10 women and 4 men, ranging in age from 24 to 60 years (mean, 41 years; median, 39.5 years) (Table 1). Five patients were older than 50 years at onset. Ocular involvement was monocular when first seen in 13 patients and binocular in 1 (patient 12). Thus, data for 15 eyes were analyzed.

All patients had symptoms of visual loss, eye pain, or both. Eight patients had visual loss and eye pain that was commonly exacerbated by eye movement. Pain was absent in 1 patient (patient 2) at onset but developed 3 months later. Pain was not associated with subjective visual loss
in 5 eyes (patients 1, 4, 9, 12, and 13). Visual loss was variably described as blurring, dimming, splotches, or a “spot” in vision.

Pertinent findings are summarized in Table 1. The visual acuity when first seen was 20/20 or better in 8 (53%) of the 15 eyes. The results of the visual field examination were normal in 2 (13%) of the 15 eyes. Three eyes demonstrated an arcuate defect, and 4 had a paracentral scotoma. A central scotoma or central depression was found in 3 eyes, and only a remaining peripheral island remained when 2 additional eyes (patients 1 and 5) were tested. Mild ptosis was seen in 2 patients (patients 6 and 9), and developed later in the course of 2 additional eyes (patients 2 and 14).

Magnetic resonance imaging scans demonstrated enhancement around the intraorbital optic nerve in 13 patients. In 1 patient (patient 14), enhancement appeared to involve the full thickness of the optic nerve, and in this patient the diagnosis was based on pathologic examination results. In another patient (patient 8), the MRI scan showed sheath and optic nerve enhancement. There was intracranial extension in 3 patients (patients 2, 8, and 14). None of the scans revealed white matter lesions.

All patients had normal laboratory test results, except 1 (patient 7) in whom the fluorescent treponemal antibody absorption test result was weakly positive. In this patient, the results of confirmatory serologic tests (the VDRL test and microhemagglutination–treponemal pallidum) and the cerebrospinal fluid fluorescent treponemal antibody absorption test were negative. A biopsy specimen of the optic nerve lesion in 2 patients (patients 2 and 14) showed acute and chronic inflammatory changes without granulomas or vasculitis (Figure 1). All 3 patients with intracranial extension underwent an expanded evaluation for granulomatous disease, including testing for antineutrophil cytoplasmic antibodies (perinuclear–antineutrophil cytoplasmic antibody and cytoplasmic–antineutrophil cytoplasmic antibody) and chest radiography. The results of these studies were normal.

Twelve patients were treated initially with prednisone, typically 60 or 80 mg/d, and 2 were treated initially with indomethacin. All experienced dramatic relief of eye pain, usually within 24 hours of starting treatment, and prompt improvement of vision (within days of initiating corticosteroid therapy). Four patients had a relapse when the corticosteroid dose was reduced, necessitating the use of additional treatment modalities, including intravenous methylprednisolone (2 patients), peribulbar corticosteroids (1 patient), azathioprine (2 patients), and radiation therapy (2 patients). The visual acuity was 20/25 or better in 12 (80%) of the 15 eyes. Two patients (patients 2 and 14) experienced a poor visual outcome, in each instance associated with a delay in initiating corticosteroid treatment (Table 2). Follow-up intervals ranged from 1 month to 6 years (mean, 12½ months; median, 9½ months) (Table 2).

PATIENT 1

A 26-year-old woman developed right retro-orbital pain exacerbated by eye movement and mild photophobia 2 weeks following an upper respiratory tract infection. The results of an ophthalmologic examination 2 weeks after onset revealed right optic disc edema and subjective color desaturation; otherwise, the test results of optic nerve function were normal. An MRI scan showed enhancement around the right optic nerve (Figure 2). Two weeks later, she began treatment with prednisone, 40 mg/d, which was tapered over 12 days. This brought prompt relief of pain, but the visual acuity declined from 20/20 to 20/40 OD. Eight weeks after the onset of symptoms, she was seen in neuro-ophthalmologic consultation. Her visual acuity was 20/80 OD and 20/20 OS. Goldmann perimetry in the right eye showed an absolute inferior arcuate scotoma plus a smaller superior scotoma (Figure 3). The visual field in the left eye was normal. There was a +2 right relative afferent papillary defect. The results of external biomicroscopy and ocular motility examinations were normal. The results of a fundus examination revealed moderate hyperemic right optic disc edema and a normal left optic disc (Figure 4).

Additional laboratory testing included the determination of the complete blood cell count, the erythrocyte...
sedimentation rate, and the levels of antinuclear antibodies and angiotensin-converting enzyme and the performance of a syphilis serologic test and chest radiography; the results of all tests were normal or negative. Corticosteroid treatment was reinstituted, starting this time at 80 mg/d and decreasing by 20 mg/wk. The results of reexamination 4 weeks later showed improvement of the visual acuity to 20/20 OD. The visual field was also much improved, and the disc was mildly pale. Reexamination 5 weeks later showed no change in visual acuity, but visual field testing revealed mild additional central depression in the left eye. He received a course of prednisone, 80 mg/d, which was tapered over 4 weeks. Optic nerve function improved; however, 2 months later he experienced abrupt onset of severe left retro-orbital pain with worsening of vision. He did not seek medical attention until 1 month later, at which time an MRI scan demonstrated enhancement around the apical portion of the left optic nerve with extension intracranially (Figure 5).

**PATIENT 2**

A 37-year-old previously healthy man experienced “foggy” vision in his left eye accompanied by a few sparkles of light. He had a sensation of heaviness of the involved eye but no actual eye pain and no discomfort with eye movement. The results of an eye examination 2 weeks after onset showed a visual acuity of 20/60 OS, with a 0.9–log unit relative afferent pupil defect and normal optic discs. Goldmann perimetry in the left eye revealed mild central depression and a small scotoma inferior to fixation. Laboratory test results were all normal or negative, and an MRI scan of the head and orbits was interpreted as normal. Reexamination 5 weeks later showed no change in visual acuity, but visual field testing revealed mild additional central depression in the left eye. He received a course of prednisone, 80 mg/d, which was tapered over 4 weeks. Optic nerve function improved; however, 2 months later he experienced abrupt onset of severe left retro-orbital pain with worsening of vision. He did not seek medical attention until 1 month later, at which time an MRI scan demonstrated enhancement around the apical portion of the left optic nerve with extension intracranially (Figure 5).

### Table 1. Clinical Features When Initially Seen

<table>
<thead>
<tr>
<th>Patient No./Sex/Age, y</th>
<th>Symptoms</th>
<th>Medical History</th>
<th>VA in the Involved Eye</th>
<th>VF Findings</th>
<th>Optic Disc Findings</th>
<th>Other Examination Findings</th>
<th>MRI Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/F/26</td>
<td>Pain with EM</td>
<td>Preceding URTI</td>
<td>20/20</td>
<td>Inferior arcuate defect</td>
<td>Edema</td>
<td>. . .</td>
<td>CNS enhancement and within-orbital fat</td>
</tr>
<tr>
<td>2/M/37</td>
<td>Foggy vision and pain 3 mo later</td>
<td>None</td>
<td>20/60</td>
<td>Inferior paracentral scotoma</td>
<td>Normal</td>
<td>Mild ptosis and decreased upward gaze later</td>
<td>. . .</td>
</tr>
<tr>
<td>3/M/53</td>
<td>Pain with EM and “splotches” with exercise</td>
<td>Remote CRVO</td>
<td>20/20</td>
<td>Superior arcuate defect</td>
<td>Normal</td>
<td>. . .</td>
<td>Thickened ONS with enhancement</td>
</tr>
<tr>
<td>4/F/32</td>
<td>Pain on EM</td>
<td>Asthma</td>
<td>20/20</td>
<td>Superior paracentral scotoma</td>
<td>Normal</td>
<td>. . .</td>
<td>CNS enhancement</td>
</tr>
<tr>
<td>5/F/31</td>
<td>Pain with EM, blurring, and diplopia</td>
<td>None</td>
<td>20/20</td>
<td>Normal</td>
<td>Edema</td>
<td>Small left hypertropia</td>
<td>CNS enhancement</td>
</tr>
<tr>
<td>6/F/32</td>
<td>Pain on EM and film over vision</td>
<td>None</td>
<td>20/25</td>
<td>Inferior paracentral scotoma</td>
<td>Normal</td>
<td>Slight ptosis</td>
<td>Subtle ONS enhancement</td>
</tr>
<tr>
<td>7/F/55</td>
<td>Pain, diplopia, and a “spot” in vision</td>
<td>Postoperative DVT</td>
<td>20/300</td>
<td>Central scotoma</td>
<td>Normal</td>
<td>Mild abduction deficit and right HT</td>
<td>CNS enhancement</td>
</tr>
<tr>
<td>8/F/60</td>
<td>Decreased vision and edema on EM</td>
<td>HT and osteoarthritis</td>
<td>20/40</td>
<td>Small central scotoma</td>
<td>Moderate edema</td>
<td>1-mm ptosis</td>
<td>Enhancement of the optic nerve and orbital fat</td>
</tr>
<tr>
<td>9/F/57</td>
<td>Pain with EM, slight ptosis, and conjunctival injection</td>
<td>Meniere disease and a preceding febrile illness</td>
<td>20/30</td>
<td>Enlarged blind spot</td>
<td>Mild edema</td>
<td>Slight abduction deficit, slight ptosis, and mild injection over MR</td>
<td>CNS and ONS enhancement with an intracranial extension</td>
</tr>
<tr>
<td>10/M/33</td>
<td>Pain with EM and cloudy vision</td>
<td>None, but a preceding URTI</td>
<td>20/20</td>
<td>Inferior arcuate defect</td>
<td>Moderate disc edema</td>
<td>Mild injection over LR and 0.8-mm exophthalmos</td>
<td>ONS enhancement and fat</td>
</tr>
<tr>
<td>11/F/51</td>
<td>Cloudy vision and eye pain</td>
<td>None</td>
<td>LP</td>
<td>Temporal island</td>
<td>Mild to moderate edema</td>
<td>. . .</td>
<td>CNS enhancement</td>
</tr>
<tr>
<td>12/M/42</td>
<td>Eye ache in both eyes and mild dimming in the right eye</td>
<td>None</td>
<td>20/20 OD and 20/15 OS</td>
<td>Paracentral depression in the right eye and normal in the left eye</td>
<td>Mild edema in both eyes</td>
<td>. . .</td>
<td>CNS enhancement and fat</td>
</tr>
<tr>
<td>13/F/24</td>
<td>Eye pain</td>
<td>Asthma</td>
<td>20/15</td>
<td>Mild central depression</td>
<td>Mild edema</td>
<td>. . .</td>
<td>CNS enhancement and fat</td>
</tr>
<tr>
<td>14/F/42</td>
<td>Eye pain for 6 mo and decreased vision in the left eye (left ptosis 3 mo after onset)</td>
<td>None</td>
<td>CF</td>
<td>Temporal island</td>
<td>Edema and palor</td>
<td>Ptosis, eyelid edema, ophtalmoplegia, and 2-mm exophthalmos</td>
<td>Thickening and enhancement of the optic nerve with intracranial involvement</td>
</tr>
</tbody>
</table>

*VA indicates visual acuity; VF, visual field; MR, magnetic resonance imaging; EM, eye movement; URTI, upper respiratory tract infection; ONS, optic nerve sheath; CRVO, central retinal vein occlusion; DVT, deep vein thrombosis; HT, hypertension; MR, medial rectus; CN, optic nerve; LR, lateral rectus; LP, light perception; CF, counting fingers; and ellipses, data not applicable. 

©2001 American Medical Association. All rights reserved.
In retrospect, enhancement around the apical optic nerve could be identified on his initial scan as well.

His visual acuity had declined to hand motions OS, with a large dense central scotoma. He enjoyed only a modest response to intravenous methylprednisolone followed by oral prednisone. His vision worsened again 2 months later, at which time he received a course of radiation therapy consisting of 2520 rads (25.2 Gy) in 14 fractions. Recurrence of pain 4 months later was treated with low-dose alternate-day prednisone plus azathioprine. He has been stable for 18 months, since beginning this regimen.

Optic perineuritis was first described by Edmunds and Lawford in 1883. These researchers distinguished between 2 forms of the disorder: exudative and purulent. The exudative form consisted of a localized nonsuppurative pachymeningitis. The purulent form was associated with fibrosis and inflammatory infiltration. The infiltrate also extends into the pial septa by the chronic inflammatory cell infiltrate. The parenchyma of the adjacent optic nerve is slightly infiltrated by lymphocytes.

COMMENT

Optic perineuritis was first described by Edmunds and Lawford in 1883. These researchers distinguished between 2 forms of the disorder: exudative and purulent. The exudative form consisted of a localized nonsuppurative pachymeningitis. The purulent form was associated with fibrosis and inflammatory infiltration.
graphic, and pathologic features of 4 patients with OPN sheath.6 Other focal forms of orbital inflammatory disease main focus of the inflammatory response is the optic nerve

gnate a form of orbital inflammatory disease in which the
cept that the inflammatory infiltrate is loosely orga-
said to be normal, an observation consistent with the con-
many such cases of OPN, optic nerve function has been
ated with leptomeningitis that had extended to involve
the subarachnoid space surrounding the optic nerves. In
many such cases of OPN, optic nerve function has been
d said to be normal, an observation consistent with the con-
cept that the inflammatory infiltrate is loosely organ-
zied around the optic nerve.

More recently, the term OPN has been used to des-
ignate a form of orbital inflammatory disease in which
the main focus of the inflammatory response is the optic nerve
sheath.6 Other focal forms of orbital inflammatory disease
include periscleritis, orbital myositis, and dacryoadeniti-
s.7 Dutton and Anderson8 described the clinical, radiog-
graphic, and pathologic features of 4 patients with OPN

in whom enlargement of the intraorbital optic nerve was
thought to represent an optic nerve sheath meningioma.
Biopsy specimens, however, demonstrated inflammatory
infiltration of the dural sheath in 2 patients and dense per
neural fibrous tissue in the other 2. None were associated
with a specific inflammatory disorder. Of the 4 patients, 3
differed clinically from patients with optic nerve sheath me
ningioma in that head and eye pain was prominent. Only
1 of the 4 patients was treated with corticosteroids, which
stabilized vision for 6 months until complications led to
their discontinuation. A patient with bilateral idiopathic op
tic nerve sheath inflammation, described by Margo et al,8
did not experience a beneficial response to corticoste-
roids. A full-thickness biopsy specimen of the more se-
verely involved optic nerve revealed chronic inflamma-
tion of the optic nerve sheath with vasculitic changes
and necrobiotic granulomas. Visual loss was attributed in large
part to secondary ischemic infarction of the optic nerve,
presumably due to circumferential compression of the op
tic nerve periphery by the mass of the thickened optic nerve
sheath.8 Two similar patients, in whom visual loss was due
to vascular occlusion, were described by Winterkorn et al9;
however, a biopsy was not performed.

The pathologic changes of the optic nerve sheath and
the optic nerve that were present in our patients and in those
that have been previously described suggest that the clini-
cally defined entity of OPN likely encompasses a spec-
trum of disorders. Regardless of what unknown process in
cites the initial inflammatory process in idiopathic cases,
the common pathologic reaction consists of marked thick-
ening of the optic nerve sheath due to nonspecific fibro-
s.4 Various stages of predominantly lymphocytic infiltra-
tion are usually present. In the case reported by Margo et
al,8 foci of degenerating (necrobiotic) collagen were pres-
ent in the optic nerve sheath. Of the 4 patients described
by Dutton and Anderson,4 1 showed granulomatous in-
flammation in the sheath. Visual loss in those patients in
whom a biopsy of the optic nerve was performed or in whom
the optic nerve was excised correlated with the presence
of either optic nerve demyelination10 or infarction.8 Perv
ascular lymphocytic infiltration of small optic nerve ves-
sels (vasculitis) has been identified in some patients.7,11

In most cases of suspected OPN, an optic nerve bi-
opsy is not indicated. The diagnosis is typically based on
a combination of clinical and radiographic findings. Neur
oimaging in patients with OPN typically shows a char-
acteristic pattern of enhancement around the optic nerve

Figure 2. Patient 1. Magnetic resonance imaging scan of the head and
orbits, with contrast infusion and fat suppression. A, The axial view shows
enhancement around the right intraorbital optic nerve with some
“streakiness” of the surrounding orbital fat. R indicates right side.
B, The coronal view confirms that the enhancement is around, rather
than within, the optic nerve.

Figure 3. Patient 1. Goldmann perimetry in the right eye shows an absolute
inferior arcuate scotoma and a smaller less dense scotoma in the superior
Bjerrum area. The field in the left eye is normal.
(“tramtrack” on axial views and “doughnut” on coronal views). In addition, MRI scans in some cases show streaky enhancement of orbital fat (Figure 2). These radiographic changes are not found in patients with typical demyelinating ON. In occasional cases of OPN, the substance of the optic nerve also shows enhancement, presumably due to inflammation of intraneural pial septa as well as the nerve sheath. Two of our patients exhibited this finding, with histopathologic correlation demonstrated in 1. In some patients, close inspection may reveal subtle enhancement of extraocular muscles and/or sclera in addition to the characteristic changes in the optic nerve sheath (Figure 5). A careful inspection for these changes may be particularly helpful in cases in which the perineural findings are subtle or indeterminant and particularly in those scans that demonstrate intraneural enhancement. Computed tomographic scanning does not usually provide sufficient spatial resolution to distinguish perineural enhancement from the intraneural enhancement seen in demyelinating ON. Recent advances in MRI, specifically the use of dedicated orbital views with fat suppression and gadolinium, have enabled us to make this distinction. Accordingly, we suspect that the prevalence of this disorder has been underestimated. In the pre-MRI era, some cases of OPN may have been diagnosed as being “atypical corticosteroid-responsive ON.”

Based on shared clinical features, patients with OPN are likely to be misdiagnosed initially as having ON. Similar to those with ON, most patients with OPN are women (71% [10 of 14 patients] in our series) and most experience acute monocular visual loss accompanied by eye pain. In patients with both disorders, eye pain is commonly exacerbated by eye movement. Disc edema is often present in patients with both conditions (found in 10 of the 15 eyes in our series). Treatment considerations and prognosis, however, differ for these 2 disorders, particularly regard-
The age distribution of patients with OPN is broader, and the average age is older than in patients with ON. Our patients’ age ranged from 24 to 60 years (mean, 41 years). The average age of patients with ON is 33.5 years; only 15% of cases occur in individuals older than 50 years. In contrast, 5 (36%) of our 14 patients were older than 50 years.

The tempo and pattern of visual loss also differed in our patients compared with those with ON. In contrast to visual loss in patients with ON, which usually occurs over several days, visual loss in many of our patients with OPN progressed for several weeks before they were correctly diagnosed and treatment was initiated. Although occasional patients with ON demonstrate sparing of central vision, we found this to be a common pattern in patients with OPN. The visual acuity was 20/20 in 8 (53%) of the 15 eyes. The results of visual field testing were normal in 3 eyes; a paracentral scotoma was seen in 4, and an arcuate defect was seen in 3. Thus, 10 of the 15 eyes demonstrated sparing of central vision. In contrast, in a study of 103 patients with ON, Perkin and Rose found only 4.2% to have central sparing. In keeping with their tendency to spare central vision, the degree of dyschromatopsia was less than typically seen in patients with ON.

Mild motility disturbance, due to extraocular muscle inflammation, is occasionally a helpful feature. Four of the 14 patients had abnormal ocular motility, based either on eliciting a history of diplopia or on examination findings. One of these 4 and an additional patient exhibited mild ptosis in the involved eye, and 2 others developed mild ptosis later in their course. These are not typical features of ON (unless there is associated brainstem involvement due to multifocal demyelinating disease), and their presence in a patient suspected of having ON should suggest the alternative diagnosis of OPN.

Finally, the response to treatment may help in differentiating OPN from ON. Of our 14 patients with OPN, 12 were treated with corticosteroids, and all demonstrated dramatic relief of pain on initiating treatment, typically within hours and all within a day. Visual loss also showed prompt recovery. Relapse following discontinuation of treatment, however, was common. These features, particularly the recurrence of pain and/or visual loss on corticosteroid tapering, should suggest a diagnosis of OPN rather than ON. Specific inflammatory and neoplastic entities, such as sarcoidosis, lymphoma, leptomeningeal carcinomatosis, and some fungal infiltrations, may demonstrate a similar response to treatment. These disorders, however, soon declare themselves by demonstrating recurrence and progression with or without continued corticosteroid treatment.

The prognosis for visual outcome in patients with OPN is generally excellent. This is greatly influenced, however, by the interval between the onset of visual loss and the initiation of treatment. In 2 patients with a poor visual outcome, treatment was delayed by a month or more. The other factor that influences prognosis is the frequency of recurrent attacks. Initiating treatment with higher doses of corticosteroids (eg, prednisone, 80 mg/d) and more prolonged treatment at this level appear to lessen the likelihood of recurrent attacks.

The possibility of OPN should be considered in all patients in whom ON is diagnosed. Magnetic resonance imaging is particularly important in patients with clinical findings that are atypical for demyelinating ON. Specifically, these would include age older than 45 years, sparing of central vision, visual loss progressing for longer than 2 weeks, persistence of disc edema, recurrence of pain, and visual loss after discontinuing corticosteroid therapy. Patients in whom pain is particularly severe or is out of proportion to visual loss might also be considered in this category. Careful scrutiny, in terms of history and physical examination, for evidence of orbital involvement (diplopia, subtle ptosis, and chemosis) may also help to identify these patients.

It is important to accurately distinguish between OPN and ON for 2 reasons. First, the prognosis is different in these disorders. Patients with ON are at high risk of developing multiple sclerosis and should be counseled accordingly. Patients with OPN, in contrast, are not at increased risk for demyelinating disease but are likely to experience a recurrence of visual loss in the future. Second, treatment considerations differ for the 2 entities. Corticosteroids have not been shown to influence the visual outcome in patients with ON and, therefore, many patients with ON are managed expectantly (ie, without treatment). Patients with OPN, however, will continue to lose vision, in some cases irreversibly, unless treated with corticosteroids or other anti-inflammatory agents. Furthermore, the dosage and route of administration differ. The recommended regimen for OPN (oral prednisone, 80 mg/d) is contraindicated in patients with ON because of the association of this treatment with recurrences of ON. On the other hand, the rather short (2-week) course of corticosteroid treatment used in patients with ON is not long enough to achieve lasting remission in most patients with OPN.

Table 3. Features That Distinguish Optic Neuritis From Optic Perineuritis

<table>
<thead>
<tr>
<th>Feature</th>
<th>Optic Neuritis</th>
<th>Optic Perineuritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at onset</td>
<td>Usually young adults (only 15% are &gt;50 y)</td>
<td>Broader range (36% are &gt;50 y)</td>
</tr>
<tr>
<td>Visual loss</td>
<td>Usually central</td>
<td>Often paracentral or arcuate</td>
</tr>
<tr>
<td>Time course</td>
<td>Progression over days</td>
<td>Progression over weeks</td>
</tr>
<tr>
<td>Natural history</td>
<td>Spontaneous recovery</td>
<td>Progressive visual loss</td>
</tr>
<tr>
<td>Response to corticosteroid treatment</td>
<td>Variable; uncommon relapse after stopping</td>
<td>Prompt and dramatic; common relapse after brief treatment</td>
</tr>
<tr>
<td>Magnetic resonance imaging scan findings</td>
<td>Optic nerve enhancement with or without white matter lesions</td>
<td>Perineural enhancement and &quot;streaky&quot; fat with or without extracocular muscle enhancement</td>
</tr>
</tbody>
</table>

The frequency of recurrent attacks is the frequency of recurrent attacks. Initiating treatment with higher doses of corticosteroids (eg, prednisone, 80 mg/d) and more prolonged treatment at this level appear to lessen the likelihood of recurrent attacks.

The possibility of OPN should be considered in all patients in whom ON is diagnosed. Magnetic resonance imaging is particularly important in patients with clinical findings that are atypical for demyelinating ON. Specifically, these would include age older than 45 years, sparing of central vision, visual loss progressing for longer than 2 weeks, persistence of disc edema, recurrence of pain, and visual loss after discontinuing corticosteroid therapy. Patients in whom pain is particularly severe or is out of proportion to visual loss might also be considered in this category. Careful scrutiny, in terms of history and physical examination, for evidence of orbital involvement (diplopia, subtle ptosis, and chemosis) may also help to identify these patients.

It is important to accurately distinguish between OPN and ON for 2 reasons. First, the prognosis is different in these disorders. Patients with ON are at high risk of developing multiple sclerosis and should be counseled accordingly. Patients with OPN, in contrast, are not at increased risk for demyelinating disease but are likely to experience a recurrence of visual loss in the future. Second, treatment considerations differ for the 2 entities. Corticosteroids have not been shown to influence the visual outcome in patients with ON and, therefore, many patients with ON are managed expectantly (ie, without treatment). Patients with OPN, however, will continue to lose vision, in some cases irreversibly, unless treated with corticosteroids or other anti-inflammatory agents. Furthermore, the dosage and route of administration differ. The recommended regimen for OPN (oral prednisone, 80 mg/d) is contraindicated in patients with ON because of the association of this treatment with recurrences of ON. On the other hand, the rather short (2-week) course of corticosteroid treatment used in patients with ON is not long enough to achieve lasting remission in most patients with OPN.
REFERENCES
